Proton pump inhibitors and clopidogrel: is it a significant drug interaction?

Bibliography

• Antman EM, Hand M, Armstrong PW, 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-Elevation myocardial infarction. Circulation 2008;117:296-329
   PubMed Web of Science ®Google Scholar
• Fraker TD Jr, Fihn SD, Writing on behalf of the 2002 Chronic Stable Angina Writing Committee, 2007 Chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina. Circulation 2007;116:2762-72
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM, ACC/AHA 2007 Guidelines for the management of patients with unstable angina/Non-ST-Elevation myocardial infarction. J Am Coll Cardiol 2007;50:e1-157
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-39
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Keith AAF, Hacke W, Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17
   PubMed Web of Science ®Google Scholar
• Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007;357:2482-94
   PubMed Web of Science ®Google Scholar
• Patrono C, Baigent C, Hirsh J, Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines. 8th edition. Chest 2008;133:199S-233
   PubMedGoogle Scholar
• Bhatt DL, Scheiman J; Writing Committee Members, ACCF/ACG/AHA 2008 Expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. Circulation 2008;118:1894-909
   PubMed Web of Science ®Google Scholar
• Juurlink DN, Gomes T, Dennis TK, A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-8
   PubMed Web of Science ®Google Scholar
• Ho PM, Thomas MM, Wang L, Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-44
   PubMed Web of Science ®Google Scholar
• Farid NA, Payne CD, Small DS, Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-41
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008;156:10S-5S
   PubMed Web of Science ®Google Scholar
• Brandt JT, Payne CD, Wiviott SD, A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007;153:66. e9-16
   PubMed Web of Science ®Google Scholar
• Li X, Andersson TB, Ahlstrom M, Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-7
   PubMed Web of Science ®Google Scholar
• Gilard M, Arnaud B, Gal GL, Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. JTH 2006;4:2508-9
   Google Scholar
• Gilard M, Arnaud B, Cornily Jean-Christophe, Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60
   PubMed Web of Science ®Google Scholar
• Bonello L, Paganelli F, Arpin-bornet M, Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. JTH 2007;5:1630-1636
   Google Scholar
• Siller-Matula J, Alexander OS, Irene ML, Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148. e1-5
   PubMed Web of Science ®Google Scholar
• Sibbing D, Morath T, Stegherr J, Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. JTH 2009;101:714-19
   Google Scholar
• Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008;52:1038-a-1039
   Web of Science ®Google Scholar
• Aubert RE, Epstein RS, Teagarden JR, Abstract 3998: proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study. Circulation 2008;118:S_815
   Google Scholar
• Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:699-700
   PubMed Web of Science ®Google Scholar
• Stanek EJ, Aubert RE, Flockhart DA, A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the clopidogrel Medco outcomes study. SCAI Scientific sessions; 2009
   Google Scholar
• Dunn SP, Macaulay TE, Brennan DM, Abstract 3999: baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008;118:S_815-a
   Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-75
   PubMed Web of Science ®Google Scholar
• O'Donoghue ML, Braunwald E, Antman EM, Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009;374:989-97
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer B, Contant CF, COGENT: a prospective, randomized, placebo-controlled trial of omeprazole in patients receiving aspirin and clopidogrel. Transcatheter Cardiovascular Therapeutics 2009 Available from: http://assets.cardiosource.com/Bhatt_COGENT.ppt [Last accessed 29 September 2009]
   Google Scholar
• Wood S. COGENT-1 trial scrapped, sponsor declares bankruptcy. Theheart org 2009. Available from: www.theheart.org/article/936651.do. [Last accessed 9 October 2009]
   Google Scholar
• Mega JL, Close SL, Wiviott SD, Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354-62
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Grady D, Rubin SM, Petitti DB, Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37
   PubMed Web of Science ®Google Scholar
• Bhindi R, Ormerod O, Newton J, Interaction between statins and clopidogrel: is there anything clinically relevant? QJM 2008;101:915-925
   PubMed Web of Science ®Google Scholar
• Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Information for healthcare professionals: Food and Drug Administration, 2009. Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/DrugSafetyInformationforHeathcare Professionals/ucm190787.htm. [Last accessed 17 January 2010]
   Google Scholar
• Clopidogrel. Prescribing information. Bristol-Myers Squibb/Sanofi Pharmaceuticals partnership. Bridgewater; 2009
   Google Scholar
• Chan FKL, Chung SCS, Suen BY, Preventing recurrent upper gastrointestinal bleeding in patients with helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73
   PubMed Web of Science ®Google Scholar
• Taha AS, McCloskey C, Prasad R, Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 2009;374:119-25
   PubMed Web of Science ®Google Scholar
• Prasugrel. FDA Cardiovascular and Renal Drugs Advisory Committee briefing Document, 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/CardiovascularandRenal DrugsAdvisoryCommittee/UCM181185.pdf [Last accessed 9 October 2009]
   Google Scholar